{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:15:43Z","timestamp":1790946943475,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000222","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-16-00013163"],"award-info":[{"award-number":["G-16-00013163"]}],"id":[{"id":"10.13039\/501100000222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-159928"],"award-info":[{"award-number":["FDN-159928"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtha.2023.04.021","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T11:41:50Z","timestamp":1682509310000},"page":"1692-1702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["News at XI: moving beyond factor Xa inhibitors"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-0754","authenticated-orcid":false,"given":"James C.","family":"Fredenburgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.04.021_bib1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.04.021_bib2","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.021_bib3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42444-021-00053-9","article-title":"Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants","volume":"23","author":"Park","year":"2022","journal-title":"Int J Arrhythm"},{"key":"10.1016\/j.jtha.2023.04.021_bib5","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study","volume":"9","author":"Sanghai","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2023.04.021_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MBC.0000000000001153","article-title":"Comparing the efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis","volume":"33","author":"Wu","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2023.04.021_bib7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A\u00a0comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)","volume":"163","author":"Van de Werf","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2023.04.021_bib8","unstructured":"Artivion. Artivion follows recommendation to stop PROACT Xa\u00a0clinical trial. https:\/\/investors.artivion.com\/news-releases\/news-release-details\/artivion-follows-recommendation-stop-proact-xa-clinical-trial 2023. [accessed March 27, 2023]."},{"key":"10.1016\/j.jtha.2023.04.021_bib9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOH.0b013e3283497e61","article-title":"Factor XI and XII as antithrombotic targets","volume":"18","author":"M\u00fcller","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtha.2023.04.021_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.04.021_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0037-1616203","article-title":"Roles of platelets and factor XI in the initiation of blood coagulation by thrombin","volume":"86","author":"Walsh","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib13","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-07-368811","article-title":"Polyphosphate is a cofactor for the activation of factor XI by thrombin","volume":"118","author":"Choi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.021_bib14","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1055\/a-1336-0526","article-title":"Polyanions in coagulation and thrombosis: focus on polyphosphate and NETs","volume":"121","author":"Rangaswamy","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"Duga","year":"2013","journal-title":"Sem Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199107183250303","article-title":"Factor XI deficiency in Ashkenazi Jews in Israel","volume":"325","author":"Asakai","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2023.04.021_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2023.04.021_bib20","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/STROKEAHA.118.022792","article-title":"Genetically determined FXI (Factor XI) levels and risk of stroke","volume":"49","author":"Gill","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2023.04.021_bib21","article-title":"Genetically proxied inhibition of coagulation factors and risk of cardiovascular disease: a Mendelian randomization study","volume":"10","author":"Yuan","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2023.04.021_bib22","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with decreased risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.021_bib23","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.021_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2007.02530.x","article-title":"Evidence of a U-shaped association between factor XII activity and overall survival","volume":"5","author":"Endler","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1126\/science.abn0910","article-title":"Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure","volume":"377","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jtha.2023.04.021_bib27","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.943738","article-title":"Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study","volume":"122","author":"Siegerink","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.04.021_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2023.04.021_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0038-1653750","article-title":"Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study","volume":"73","author":"Bolton-Maggs","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.04.021_bib32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/psp4.12663","article-title":"PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2023.04.021_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad123","article-title":"Reversal agents for current and forthcoming direct oral anticoagulants","volume":"44","author":"van Es","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2023.04.021_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jtha.2023.04.021_bib36","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib37","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib39","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib40","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.04.021_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in\u00a0vitro studies and in\u00a0vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.021_bib42","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2023.04.021_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.04.021_bib44","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A\u00a0multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.04.021_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.04.021_bib46","author":"Sharma"},{"key":"10.1016\/j.jtha.2023.04.021_bib47","article-title":"On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: association with treatment effects","volume":"40","author":"Hutto","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jtha.2023.04.021_bib48","doi-asserted-by":"crossref","first-page":"f11","DOI":"10.1093\/ehjcvp\/pvab002","article-title":"Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients","volume":"7","author":"Menichelli","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2023.04.021_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Atlas ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.04.021_bib50","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623003434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623003434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:39:18Z","timestamp":1761536358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623003434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1538783623003434"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.04.021","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"News at XI: moving beyond factor Xa inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}